Introduction
The cloning and characterization of several human genes P815 tumor model is an ideal murine system for the study of anti-tumor immunization schemes (1,5-10). One advantage encoding antigens specifically expressed on tumor cells but not most normal cells has opened the way for the antigenof this system is the availability of a highly transfectable variant of P815, P1.HTR (11). specific immunization of cancer patients (1-4). Immunization approaches will depend on the activation of class I MHCDespite expression of recognizable antigens, tumors grow progressively in immunocompetent hosts, implying the existrestricted CD8 ϩ T lymphocytes. Because of the complexities of T cell regulation, provision of cofactors and co-stimulator ence of mechanisms for tumor escape from immune destruction. Several progressor tumor cell lines have been transfected molecules necessary for differentiation into highly lytic effector cells may be a required component of tumor antigen immunizto express the T cell co-stimulator molecule B7-1, resulting in their rejection by immunocompetent syngeneic mice (12-ation protocols. Because of many parallels with human tumors expressing defined tumor antigens, the well-characterized 16). It therefore has been postulated that failure of tumor rejection may be a consequence of the absence of B7 the University of Chicago. Female mice 8-10 weeks of age expression by tumor cells, which in turn results in the induction were used for experiments. of tumor-specific T cell anergy and systemic tolerance. HowCells and transfectants ever, other mechanisms of tumor escape certainly exist. Numerous studies have suggested that transfection of tumors The P1 subclone of the DBA/2-derived mastocytoma P815, to express other immunomodulatory molecules also results in its highly transfectable variant P1.HTR and the multiple antigen their rejection in vivo, leading to protection against tumor loss variant P0.HTR were derived and cultured as described challenge (17-22).
(7,11). P1 cells were used as targets for cytolytic assays and We recently have focused on analyzing the immune P1.HTR cells as recipients for transfection. The irrelevant response generated against immunogenic tumors that are syngeneic tumor L1210 was grown as described (25) and naturally rejected, in order to identify cofactors and cytokines used as a negative control target in cytolytic assays. The NKthat participate in a successful anti-tumor response when it sensitive target YAC-1 was cultured in DMEM containing 10% does occur, which in turn may indicate factors that are FCS, 2-mercaptoethanol, and additional glucose and amino deficient in the case of progressive tumors. Natural rejection acids (25) . of tum -variants of P815 was blocked by a murine CTLA-4-
The cDNAs encoding murine B7-1, IL-12 p35 and IL-12 murine IgG3 fusion protein (mCTLA-4γ3), indicating that host p40 were cloned by PCR as described (25) . The IL-12 inserts B7 family co-stimulation was indeed necessary for generation were subcloned into pEF.BOS.puro for supertransfection into of tumor-specific cytotoxic T lymphocytes (CTL) (23). Tumor P1.HTR cells that had been transfected previously with empty rejection also was prevented by an anti-IL-12 antiserum, pCDSRa (generating HTR.C) or pCDSRa.B7-1 (generating indicating the importance of host IL-12 for generating an HTR.B7-1). HTR.C cells were used as control transfectants anti-tumor response (24) . In addition, rejection appeared to for in vivo experiments. Transfection using both IL-12 subunits correlate with a high IFN-γ-/low IL-4-producing T cell phenoor an empty vector control was performed by calcium phostype in draining lymph nodes, the generation of which also phate precipitation as described (11) and selection was was prevented by IL-12 blockade, suggesting that a T h 1/T c 1-performed with puromycin (1 µg/ml). Drug-resistant cells were like cytokine profile was predictive of, and necessary for, cloned by limiting dilution, screened for IL-12 secretion and successful tumor rejection (24) . In addition, primary genermatched for expression of class I MHC molecules (yielding ation of anti-tumor CTL in vitro was optimized by provision of HTR.C/C, HTR.B7-1/C, HTR.C/IL-12 and HTR.B7-1/IL-12). The both B7-1 and IL-12 (25), the combination resulting in chosen clones secreted~1000 U/ml IL-12 activity per 10 6 cells increased expression of cytotoxic granule-related serine in 24 h as measured by proliferation of murine concanavalin A esterase and a high IFN-γ-producing phenotype. Collectively, blasts (26) ; control transfectants produced no detectable these results have implicated synergistic co-operation IL-12 activity. rIL-12 was produced as a histidine-tagged between B7-1 and IL-12 in the induction of a T h 1/T c 1-like T fusion protein in P1.HTR cells and purified by nickel chelate cell phenotype, which may be optimal for mediating tumor chromatography as described (24) . rejection. Ensuring appropriate activation towards this phenotype might therefore induce rejection of progressively growing
Immunization with irradiated tumor cell transfectants established tumors, which otherwise might fail to elicit a T h 1-Either naive DBA/2 mice or mice bearing a s.c. HTR.C tumor like response.
(5ϫ10 5 cells on the left flank) were immunized. Cultured In order to move toward a clinically applicable system, we P1.HTR transfectants were washed three times with PBS, have employed an immunization scheme employing irradiated adjusted to 1ϫ10 8 cells/ml and irradiated (10,000 rad). Mice rather than living tumor cell transfectants. We have observed received 50 µl per hind footpad (5ϫ10 6 cells) via a 26-gauge previously that multiple immunizations with irradiated B7-1-needle each week for three consecutive weeks. Two weeks but not B7-2-transfected P1.HTR cells was sufficient to induce after the last injection, either splenocytes were stimulated in tumor-specific CTL and protection against living tumor a mixed lymphocyte tumor culture (MLTC) or mice were challenge in the majority of naive mice (23). However, in the challenged with a s.c. inoculum of 5ϫ10 5 living HTR.C cells present study, the same immunization approach had no effect in 50 µl PBS. In the latter case, mice were scored for incidence on the growth rate of pre-established tumors. On the contrary, of macroscopic tumor 4 weeks after the challenge, positive immunization with irradiated IL-12 transfectants did successtumors were measured in two dimensions, and a mean and fully induce regression of pre-established tumors, by a SEM for each experimental group were calculated. mechanism dependent upon B7 family co-stimulation from the host. Thus, provision of exogenous IL-12 may be more
Rejection of B7 transfectants in tumor-bearing mice critical than supplying exogenous B7 during active immuniz-HTR.C cells (5ϫ10 5 ) were implanted s.c. on the right flank of ation in the pre-established tumor setting. Our results are multiple mice. At various times after (day 0, day 4, day 7 or consistent with a model of incomplete differentiation toward day 14), HTR.B7-1 cells were implanted s.c. on the left flank. a T h 1/T c 1 phenotype as a cause for failure to reject a proBoth tumors were measured in two dimensions at least twice gressor tumor.
weekly, and a mean and SEM for each group of mice were calculated. Methods
MLTC and cytolytic assays Mice
Splenocytes (6ϫ10 6 ) from treated DBA/2 mice were stimulated DBA/2 mice were bred and housed in a specific pathogenfree animal facility at the Catholic University of Louvain or at with irradiated (5000 rad) HTR.B7-1 cells (2ϫ10 5 ) in a volume of 2 ml. After 6 days, effector cells from three replicate wells were collected and washed, adjusted to 2ϫ10 6 /ml, and titrated in duplicate in V-bottom microtiter plates to give the indicated E:T ratios, along with 2000 51 Cr-labeled target cells (either P1, L1210 or YAC-1). Supernatants were collected after 4 h and radioactivity was measured using a 96-well plate γ-counter (Wallac Microbeta, Turku, Finland). Percent specific lysis was calculated as described (27) .
IFN-γ assay
After a 6 day MLTC, effector cells were harvested and restimulated with P1 cells. After 24 h, supernatants were collected and levels of IFN-γ were assessed using a specific ELISA (the reagents having been kindly provided by Dr R. Schreiber, Washington University, St Louis, MO). Serial dilutions of test supernatants were compared to serial dilutions of a defined standard, and concentrations were calculated and expressed as U/ml.
Production of and treatment of mice with mCTLA-4γ3 mCTLA-4γ3) as described (23). The IgG3 isotype was chosen Bidimensional measurements were recorded at the indicated times.
to minimize binding to FcγRs, thus eliminating potential artifacts derived from cross-linking of B7 family molecules on the cells which express them. For preparation of large quantities of mCTLA-4γ3, P1.HTR cells expressing this protein were Results cultured in 10 l batches. Supernatant was harvested, cells were cleared by centrifugation and then ultracentrifugation,
Immunization of mice with irradiated B7-1 transfectants has and purification was performed by binding to Protein Ano effect on the growth of pre-established tumors Sepharose, elution at pH 3.0 and dialysis against PBS. Yield
In order to more closely approximate the clinical scenario was generally 1-2 mg/l of supernatant. Purification of control with cancer patients, an immunization model of P1.HTR IgG3 was similarly performed from C3110 supernatant.
tumor-bearing rather than naive mice was employed. Given For treatment of mice, purified mCTLA-4γ3 and control IgG3 the prior successes of immunization with irradiated B7-1-were adjusted to 100 µg/ml in PBS. Mice received 1 ml i.p. transfected P1.HTR cells in naive mice (23), these transfecof either of these reagents on days 0, 1, 2, 4, 7, 10, 14, 17, tants were the first to be examined in a pre-established 21 and 24. Tumor cells were implanted in the flank a few tumor setting. Control-transfected P1.HTR cells (HTR.C) hours after the first injection on day 0. No apparent toxicities were implanted s.c. on the flank, and beginning on day 7, were observed. In other experiments, HTR.C cells were mice were immunized with irradiated B7-1 or control implanted s.c. first and administration of mCTLA-4γ3 or control transfectants in both hind footpads on a weekly schedule. IgG3 was initiated 1 h prior to immunization with irradiated As shown in Fig. 1 , none of these immunization approaches HTR.IL-12 cells, according to the same schedule. In some had any impact on the progressive growth of pre-estabexperiments, T cells were depleted by administration of antilished tumors. Thy-1 mAb (A6-703-A8) in the form of 1 ml of ascites on day -2 followed by 0.5 ml weekly.
Mice bearing large P1.HTR tumors can reject living B7-1 transfectants Flow cytometry (FCM)
It was conceivable that immunization in the pre-established tumor setting failed because of an inability of T cells from Cells were prepared from the right popliteal lymph node of mice that had received HTR.C/C or HTR.C/IL-12 cells (1ϫ10 6 ) tumor-bearing mice to respond to B7 co-stimulation, perhaps because of clonal anergy having been induced. To this 4 days earlier. Staining was performed with directly coupled mAb specific for B7-1 or B7-2 (PharMingen, San Diego, end, living HTR.C cells were implanted s.c. on the right flank of several groups of seven mice each. At various CA) and biotinylated anti-MAC-1 produced in our laboratory, followed by streptavidin-phycoerythrin or streptavidin-FITC.
times later, living HTR.B7-1 cells were implanted s.c. on the left flank. As shown in Fig. 2 (A), the growth rate of the Gates were set using second-step reagents alone. Data were collected on 20,000 viable cells based on forward light original HTR.C implant was comparable between groups. Interestingly, even in mice in which an HTR.C tumor had scatter and side scatter using a FACScan, and processed via CellQuest software (Becton Dickinson, Mountain View, been pre-established for 2 weeks (thus generating a tumor size of~1 cm), the B7-1 transfectant was readily rejected CA) . on the contralateral flank (Fig. 2B) . Thus, tumor-bearing
Immunization of naive mice with irradiated P1.HTR transfectants expressing B7-1 and/or IL-12 mice could indeed reject a tumor in a B7-dependent fashion. In addition, rejection of HTR.B7-1 did not affect It was conceivable that an IL-12-dependent, T h 1-like phenothe growth rate of the initial HTR.C implant, consistent with type might be better equipped to penetrate and eliminate an the initial observation that provision of B7-1 during active established tumor. Given the known co-operation between tumor immunization might not be sufficient to induce B7-1 and IL-12 in CTL maturation, it seemed logical to provide rejection of pre-established tumors.
both B7-1 and IL-12 during active immunization in vivo. To verify that the rejection of the HTR.B7-1 cells in HTR.C P1.HTR cells were co-transfected to express B7-1 and/or tumor-bearing mice was still mediated by T cells, T cells were IL-12; control cells and single expressors were super-transdepleted in some mice prior to challenge with the B7-1-fected with the appropriate empty vector controls (thus transfected variant. As shown in Fig. 2(C) , rejection of generating HTR.C/C, HTR.B7-1/C, HTR.C/IL-12 and HTR.B7-1 cells in tumor-bearing mice was indeed dependent HTR.B7-1/IL-12). Living transfectants expressing either B7-1 on T lymphocytes, to the same extent as it was in naive mice or IL-12 were rejected when implanted s.c. in naive DBA/2 mice (data not shown). All rejecting mice developed P815- (Fig. 2D) . but expression of IL-12 alone was clearly sufficient. When mice that rejected pre-established tumors were rested for 2 weeks and re-challenged again with HTR.C cells, all mice demonstrated protective immunity (Fig. 3B ).
We next examined the effect of immunization with IL-12 transfectants on larger pre-established tumors. As shown in Fig. 4 , even when HTR.C tumors were pre-established for 2 weeks (thus generating a large tumor of approximately 1 cm in diameter), weekly immunization in the hind footpads with irradiated IL-12 transfectants markedly slowed tumor growth. The fraction of mice completely rejecting a pre-established tumor decreased as the delay before the first immunization was prolonged. Immunization schedules with injections more frequent than once per week were not attempted.
Because the pre-established tumors were implanted s.c. on the flank, it was conceivable that immunization via the hind footpads was having a potent effect because of being in continuity with a draining lymph node site of the flank region. We therefore compared i.p. injection to footpad injection. As irradiated IL-12 transfectants but not IL-12 alone induced regression of established tumors suggested that the presence of tumor antigens expressed by P1.HTR cells might be specific CTL activity detected from splenocytes after a 6-day necessary during the immunization phase.
MLTC (data not shown).
Antigen specificity of the rejection of established tumors Naive syngeneic mice were then immunized by three weekly injections of irradiated transfectants in the hind footpads and
The lack of effect of rIL-12 alone suggested the possibility that tumor antigens must be present along with IL-12 during challenged with living HTR.C cells. As shown in Table 1 , immunization with irradiated transfectants expressing either the immunization process. To examine further a potential role for antigen specificity, the effect of immunization with irradiated B7-1 or IL-12 was sufficient to prevent growth of controltransfected tumors in the majority of mice, demonstrating HTR.C/IL-12 cells on growth of an unrelated syngeneic tumor, L1210, was examined. L1210 cells are known not to express protective immunity. any of the five defined P815 tumor antigens. As depicted in Fig. 6(A) , immunization had no effect on the growth rate of P0.HTR tumors, whereas HTR.C tumors were rejected Fig. 5 (Experiment 2) , although the growth rate of preestablished L1210 tumors was slightly delayed by immunizby the majority of treated mice. To pursue this issue further, L1210 cells were transfected to express the major P815 ation with irradiated HTR.C/IL-12 cells (Fig. 5B) , clearly no mice completely rejected the tumor and the effect was tumor antigen gene, P1A, or with a control vector. These cells failed to form measurable solid tumors when implanted marginal compared to the marked growth retardation and rejection seen with HTR.C cells (Fig. 5A). s.c., but rather metastasized widely and killed recipient mice. Nonetheless, immunization with irradiated HTR.C/ILThe characterization of specific tumor antigens expressed by P1.HTR cells allowed a further investigation into the 12 cells was capable of preventing death in the majority of mice bearing L1210.P1A but not L1210.C tumors (Fig.  specificity of the rejection response. P0.HTR cells, which were selected to lack expression of the four major P815 6B). Collectively, these results argue for an antigen-specific component to successful immunization with irradiated ILtumor antigens (5), were implanted s.c. and the mice were immunized with irradiated HTR.C/IL-12 cells. As shown in 12-transfected P1.HTR cells. Immune phenotype induced by immunization with irradiated NK cells (28), lysis against the NK-sensitive target YAC-1 also B7-1-versus IL-12-transfected P1.HTR cells was assessed. Not surprisingly, immunization with irradiated IL-12 transfectants resulted in substantially greater NK activity Naive DBA/2 mice were immunized in the hind footpads with than immunization with irradiated B7-1 transfectants (Fig. 7B) . three weekly injections of irradiated P1.HTR transfectants, P815 and L1210 are known to be relatively NK resistant. and specific CTL activity was assessed from splenocytes When effector cells were harvested after MLTC and refollowing a 6 day MLTC. As shown in Fig. 7(A) , immunization stimulated with P815 cells, nearly two orders of magnitude with irradiated transfectants expressing either B7-1 or IL-12 greater IFN-γ was produced with IL-12-facilitated immunizwas sufficient to generate anti-P815 CTL activity in 100% of ation compared to B7-1-facilitated immunization (Fig. 7C) . In mice. Lysis against L1210 control cells was Ͻ15% at all parallel experiments, similar high levels of IFN-γ were effector:target ratios, demonstrating specificity (data not observed following stimulation with anti-CD3 mAb, consistent shown). Immunization with irradiated control transfectants with T cells being the source of IFN-γ production (data resulted in specific CTL in only~20% of mice (data not shown and 23). Since IL-12 is also known to facilitate activation of not shown and 24). Immunization with combined B7-1/IL-12 analyses were then performed to examine co-expression of Because of the dependence of natural rejection of immunoboth MAC-1 and B7-1 or B7-2. As shown in Fig. 9 , normal genic tumors on an endogenous CTLA-4 ligand (23), it lymph node cells contained a small number (0.2%) of MAC-1/ was surprising in the current model that immunization with B7-1 double-positive cells, which was increased 7-fold (1.4%) transfectants expressing IL-12 alone was sufficient to result in the presence of IL-12-transfected but not of control-transin such potent anti-tumor immunity in vivo. It was reasoned that fected P1.HTR cells. B7-1 expression on MAC-1 -cells was the immune response facilitated by IL-12-only-transfectants less significantly altered (2.7 to 3.3%). In contrast, an increase might indeed require co-operation with a B7 family coin the number of B7-2 ϩ cells was seen in both the MAC-1 ϩ stimulator molecule, but that it may have been provided (0.8 to 3%) and MAC-1 -(17 to 42%) subpopulations. These endogenously by host accessory cells. To test this hypothesis, changes were seen reproducibly in three experiments, with mice inoculated s.c. with living HTR.C/IL-12 cells were treated two or three independently analyzed mice per group per from day 0 with mCTLA-4γ3 to block host B7 family molecules each experiment. Inasmuch as the absolute number of lymph and tumor size was monitored over time. As shown in Fig. node cells increased~4-fold during the 4 days of tumor 8(A), the IL-12 transfectants were readily rejected s.c.; control presence (data not shown), the increase in B7 ϩ cells could transfectants grew progressively (data not shown). Adminisbe secondary to influx of new cells, proliferation of B7 ϩ cells tration of mCTLA-4γ3 but not of control IgG3 prevented this already present or induction of increased expression of B7-1 rejection and resulted in progressive tumor growth in all mice. and B7-2 on those cells. In addition, depletion of T cells with anti-Thy-1 mAb also Finally, it was of interest to determine if, like in naive mice, prevented rejection (Fig. 8A) . The dependence of rejection rejection induced by immunization of tumor-bearing mice with on T cells makes it unlikely that the reported anti-angiogenic irradiated IL-12 transfectants also depended upon a host property of IL-12 is solely responsible for the anti-tumor effect CTLA-4 ligand and T cells. As can be seen in Fig. 8(B) , this of IL-12 (29) .
was indeed the case, as rejection of pre-established tumors Because a host CTLA-4 ligand was required for rejection was prevented by treatment of mice with mCTLA-4γ3 or preof IL-12-transfected P1.HTR cells, it was conceivable that the presence of IL-12 may have resulted in increased expression treatment with anti-Thy-1 mAb.
8). The differences observed between naive and tumorbearing mice underscores the need to examine both scenarios prior to transferring protocols to human application, as cancer patients to be treated will have established disease. Surprisingly, in contrast to results in other model systems, rIL-12 alone failed to alter the growth of established P1.HTR tumors. This is probably related to the fact that, in at least one prior model, growth of the tumor used was directly inhibited by IFN-γ (32). Since IFN-γ is produced in response to IL-12 in vivo, the antiproliferative effect of this cytokine could stall tumor progression while an effective immune response developed. The growth of P1.HTR cells in vitro is unaffected by IL-12 or IFN-γ (data not shown). Nonetheless, provision of the same levels of rIL-12 at the time of implantation of P1.HTR cells did indeed prevent tumor growth (24) and IL-12-transfected P1.HTR cells were rejected in vivo (Fig. 8) . We interpret these data to imply that delivery of IL-12 along We have observed previously that~30% of DBA/2 mice prevention of tumor growth (24) . Since all mice did acquire activated T cells in that system, failure to reject did not appear to be a result of the lack of an inflammatory response nor a Discussion consequence of immune ignorance. These results suggest that incomplete T cell differentiation may be responsible for In vitro, expression of B7-1 on P1.HTR cells (along with exogenous IL-6 to amplify the newly activated T cells) is the failure of rejection of P1.HTR cells in vivo. Provision of IL-12, but not B7-1, during active tumor immunization thus sufficient to induce IL-2 production and partial differentiation of naive CD8 ϩ T cells into modestly lytic effector cells producensures differentiation into a T h 1-like phenotype and is therefore able to overcome the deficit by generating a fresh supply ing low levels of IFN-γ (25) . Only in the presence of IL-12, however, do these cells acquire maximal lytic capability and of effector cells. It was surprising at first to find that expression of IL-12 the ability to produce high quantities of IFN-γ (25) . The prediction has been that this T h 1-like phenotype would be alone, without B7-1, was sufficient to facilitate differentiation of tumor-specific CTL in vivo. However, participation of a B7 optimal for tumor rejection in vivo as well. In the present study, immunization with irradiated IL-12 transfectants family ligand still appeared to be necessary for IL-12-mediated tumor rejection, but was provided by host immune cells. induced effector cells that produced~100-fold more IFN-γ than did immunization with irradiated B7-1 transfectants, thus Recent published work has indicated the importance of host antigen-presenting cells (APC), perhaps via indirect antigen supporting the in vitro data.
Despite the lack of induction of a high IFN-γ-producing presentation and co-stimulation, in the immune response against tumors (33,34). Whether host APC were involved in phenotype, naive mice immunized with irradiated B7-1 transfectants were protected against living tumor challenge. Thus, direct or bystander co-stimulation during the immune response directed by IL-12 transfectants has not yet been expression of B7-1 [or any of several other cofactors in other systems (18)] can generate a sufficient immune response to addressed. B7-1 expression was up-regulated on MAC-1 ϩ lymph node cells, and B7-2 expression on MAC-1 ϩ and result in protection of naive mice. However, immunization with irradiated IL-12 transfectants has been the only approach to MAC-1 -populations, following exposure to IL-12 transfectants. It is not yet clear if the increase in B7 ϩ cells is a direct effect succeed in a therapeutic setting to induce regression of preestablished P1.HTR tumors. IL-12 has been shown to facilitate of IL-12 or an indirect consequence of the type of immune response that evolves in the presence of IL-12. Preliminary rejection of established tumors in other models as well (22, 30, 31) . Perhaps a T h 1/T c 1 phenotype is better equipped attempts to neutralize IFN-γ activity have failed to prevent this effect. It is possible that another mediator is involved and that to home to and penetrate into a pre-established tumor, or cooperation with NK cells or macrophages facilitates the effector the successful immune response facilitated by IL-12 induces B7 expression as a secondary, positive reinforcement of phase of tumor rejection. Host T cells clearly were necessary for rejection induced by irradiated IL-12 transfectants (Fig. that response. The possibility that IL-12 itself can induce
